OXUR.BR Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 Apr 2024 @ 07:11):

Stats
Today's Volume	9.11M
Average Volume	105.25M
Market Cap	738 439
EPS	€0 ( 2024-04-05 )
Last Dividend	€0 ( N/A )
Next Dividend	€0 ( N/A )
P/E	0
ATR14	€0 (0.00%)

Oxurion NV Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Oxurion NV Financials

Annual	2023
Revenue:	€263 000
Gross Profit:	€104 000 (39.54 %)
EPS:	€-0.0115

FY	2023
Revenue:	€263 000
Gross Profit:	€104 000 (39.54 %)
EPS:	€-0.0115

FY	2022
Revenue:	€595 000
Gross Profit:	€-271 000 (-45.55 %)
EPS:	€-0.370

FY	2021
Revenue:	€1.13M
Gross Profit:	€516 000 (45.74 %)
EPS:	€-0.928

Financial Reports:

No articles found.

Oxurion NV

Oxurion NV, a biopharmaceutical company, develops and commercializes medicines for the treatment of eye diseases in Belgium and internationally. Its lead product is JETREA for the treatment of vitreomacular adhesion/vitreomacular traction. The company also develops THR-149, a plasma kallikrein inhibitor, which is in Phase II clinical trials for the treatment of diabetic macular edema (DME); and THR-687, an integrin antagonist which is in Phase II clinical trials for the treatment of DME. It has collaboration agreements with Bicycle Therapeutics, INC Research, and Galapagos NV. The company was formerly known as ThromboGenics NV and changed its name to Oxurion NV in September 2018. Oxurion NV was founded in 1991 and is headquartered in Leuven, Belgium.